Biomaterials Market Size and Growth
Biomaterials Market reached US$ 196.06 Million in 2025 and is expected to reach US$ 556.21 Million by 2033, growing at a CAGR of 10.7% during the forecast period 2026-2033, according to DataM Intelligence report.
The global biomaterials market is experiencing significant growth due to technological advancements in regenerative medicine, 3D printing, and the growing demand for biodegradable and bioresorbable materials. The rise in chronic conditions like cardiovascular diseases, arthritis, and orthopedic disorders necessitates implantable biomaterials. Smart biomaterials are increasingly used in drug delivery systems, wound care, and tissue engineering. Polymeric biomaterials have seen notable growth due to their adaptability and utility across multiple medical applications.
Despite challenges like stringent regulatory requirements and biocompatibility, continuous technological advancements and the expanding use of biomaterials in orthopedics, cardiovascular treatments, and wound management suggest strong potential for long-term market growth.
North America leads the market, supported by a strong healthcare infrastructure and advanced research capabilities. The Asia-Pacific region is also gaining traction due to rising healthcare investments, awareness, and an aging population in need of advanced medical solutions.
Executive Summary
For more details on this report, Request for Sample
Biomaterials Market Dynamics: Drivers & Restraints
Driver: Rise in the prevalence of chronic diseases
The global biomaterials market is growing due to the increasing prevalence of chronic diseases like cardiovascular diseases, diabetes, arthritis, and cancer. These diseases require advanced medical interventions like implants, prosthetics, stents, and drug delivery systems, which rely heavily on biomaterials for functionality and safety. Metallic and polymer-based biomaterials are crucial in orthopedic implants and drug delivery systems.
For instance, according to the National Center for Chronic Disease Prevention and Health Promotion, the US has 129 million people with at least one major chronic disease, including heart disease, cancer, diabetes, obesity, and hypertension. Five of the top 10 leading causes of death in the US are associated with preventable and treatable chronic diseases.
Over the past two decades, prevalence has steadily increased, and this trend is expected to continue. An increasing proportion of Americans are dealing with multiple chronic conditions, with 42% having two or more and 12% having at least five. Chronic diseases also significantly impact the US healthcare system, accounting for 90% of the annual $4.1 trillion expenditure.
Hence, biomaterials play a vital role in addressing these needs, as they are integral to developing implants, prosthetics, and drug delivery systems designed to manage and treat these conditions effectively.
Restraint: Risk of biomaterial-related complications
The global biomaterials market faces a significant challenge due to the risk of biomaterial-related complications. These complications can occur due to improper material selection, suboptimal manufacturing processes, or patient-specific factors.
The failure of implants or devices can lead to additional healthcare costs, extended treatments, and corrective surgeries. These complications can undermine the effectiveness of biomaterial-based solutions and affect patient outcomes, reducing confidence in these products.
Biomaterials Market Segment Analysis
The global biomaterials market is segmented based on product type, application, end user, and region.
Product Type:
The metallic biomaterials segment of the product type is expected to hold 39.74% of the biomaterials market
Metallic biomaterials, primarily made of stainless steel, titanium, and cobalt-chromium alloys, are essential in the global biomaterials market due to their excellent mechanical properties, durability, and biocompatibility. They are commonly used in orthopedic implants, dental implants, cardiovascular stents, and surgical instruments, particularly in load-bearing implants like joint replacements and bone fracture fixation.
Moreover, the demand for metallic biomaterials is growing due to the aging population and increasing prevalence of chronic conditions like arthritis, cardiovascular diseases, and osteoporosis. Advances in surface modification techniques, such as coating metallic biomaterials with biocompatible materials, are driving their use in more complex medical procedures. As these materials evolve, their role in the biomaterials market remains vital for improving healthcare outcomes and patient quality of life.
Biomaterials Market Key Players
The major global players in the biomaterials market include BASF SE, Evonik Industries AG, Royal DSM N.V., Corbion N.V., Zimmer Biomet Holdings, Inc., Medtronic plc, Stryker Corporation, Johnson & Johnson (DePuy Synthes), Smith & Nephew plc, Wright Medical Group N.V., and others.
Industry Recent Developments
- March 2026 – BASF SE develops next-generation bioresorbable polymers
BASF is advancing biodegradable polymer materials for orthopedic and dental applications, enabling faster tissue integration and reduced long-term implant complications - March 2026 – Evonik Industries AG enhances collagen and protein-based biomaterials
Evonik is focusing on collagen, gelatin, and peptide-based scaffolds for tissue engineering and regenerative medicine, improving mechanical stability and biocompatibility for clinical applications. - February 2026 – Royal DSM N.V. advances bioactive bone graft substitutes
DSM launched new calcium phosphate-based biomaterials for orthopedic and dental procedures that enhance osteointegration and reduce healing times in preclinical studies. - February 2026 – Corbion N.V. expands biodegradable polymer platform for medical devices
Corbion is developing polylactic acid (PLA)-based biomaterials for resorbable sutures, implants, and tissue scaffolds, targeting enhanced mechanical properties and controlled degradation. - January 2026 – Zimmer Biomet Holdings, Inc. introduces advanced composite biomaterials for joint implants
Zimmer Biomet launched titanium-polymer composite implants demonstrating improved wear resistance, load distribution, and patient outcomes in knee and hip replacements. - January 2026 – Medtronic plc focuses on resorbable scaffolds and vascular biomaterials
Medtronic is advancing bioresorbable scaffolds and vascular graft materials for cardiac and peripheral interventions, reducing long-term complications associated with permanent implants. In April 2025, Covation Biomaterials LLC introduced CovationBio bioPTMEG, a sustainable alternative to petroleum-based polytetramethylene ether glycol (PTMEG), offering high performance with lower environmental impact. This bio-based alternative reduces reliance on non-renewable materials while maintaining durability and resilience in high-performance applications like spandex, polyurethanes, and thermoplastic elastomers.
Market Scope
Metrics | Details | |
CAGR | 10.7% | |
Market Size Available for Years | 2023-2033 | |
Estimation Forecast Period | 2026-2033 | |
Revenue Units | Value (US$ Mn) | |
Segments Covered | Product Type | Metallic Biomaterials, Polymeric Biomaterials, Ceramic Biomaterials, Natural Biomaterials, Composite Biomaterials |
Application | Cardiovascular, Orthopedic, Dental, Ophthalmology, Wound Healing, Neurology, Others | |
End User | Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Academic and Research Institutes, Biotechnology Companies | |
Regions Covered | North America, Europe, Asia-Pacific, South America, and the Middle East & Africa | |
